AVP-V2A

AVP-V2A appears to be a code name for a drug candidate targeting the vasopressin V2 receptor (also known as AVPR2). The vasopressin V2 receptor is a G-protein-coupled receptor primarily expressed in the kidney, where it mediates the antidiuretic effects of arginine vasopressin (AVP), also called antidiuretic hormone. Activation of this receptor by AVP leads to water reabsorption in the collecting ducts, concentrating urine and maintaining water homeostasis[1][5]. Drugs that act on this pathway include agonists like desmopressin (for diabetes insipidus) and antagonists such as tolvaptan, lixivaptan, mozavaptan, and satavaptan (for hyponatremia or heart failure)[5][6]. However, there is no direct evidence from available sources that "AVP-V2A" refers to an approved or widely recognized pharmaceutical product; it may represent an investigational agent or research tool acting as either an agonist or antagonist at the vasopressin V2 receptor.